Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H101
- Development stage
- Unknown
- Lead developer
- TCRCure Biotech
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous, Intramuscular
01
Overview
H101 is a neoantigen vaccine developed by TCRCure Biotech for the treatment of Diffuse Midline Glioma (DMG). The vaccine specifically targets the H3K27M mutation, a recurrent genetic alteration found in the majority of DMG cases that creates a highly specific tumor neoantigen. By presenting this mutation-derived peptide to the immune system, H101 is designed to stimulate a targeted T-cell response against glioma cells expressing the H3K27M mutation. The program is currently in Phase 1 clinical development, aiming to provide a precision immunotherapy option for this aggressive pediatric brain tumor.
- Other names
- H101 Neoantigen vaccineH-101 Neoantigen vaccineH 101 Neoantigen vaccine
02
Targets
H3K27M (Mutant histone H3 protein containing lysine-to-methionine substitution at position 27)H3K27M (Histone H3 K27M)
Beyond the preview
Go deeper on H101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H101.